Singapore markets closed

Pfizer Inc. (PFE)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
51.08+0.95 (+1.90%)
At close: 04:03PM EST
50.79 -0.29 (-0.57%)
Pre-market: 08:58AM EST
Full screen
Trade prices are not sourced from all markets
Previous close50.13
Bid50.90 x 1800
Ask51.05 x 2900
Day's range50.28 - 51.15
52-week range41.45 - 61.71
Avg. volume20,192,709
Market cap286.728B
Beta (5Y monthly)0.64
PE ratio (TTM)9.79
EPS (TTM)5.22
Earnings date06 Feb 2023 - 10 Feb 2023
Forward dividend & yield1.60 (3.23%)
Ex-dividend date03 Nov 2022
1y target est54.78
  • Reuters

    Pfizer to invest more than $2.5 billion to expand European manufacturing

    Pfizer Inc is investing more than $2.5 billion at its drug making plants in Belgium and Ireland, gearing up to launch new products it hopes can replace lost revenue as patents expire and COVID-19 vaccine sales decline. The drugmaker said on Friday it plans to spend more than 1.2 billion euros ($1.26 billion) to expand its Puurs, Belgium manufacturing site, matching the investment at its Dublin, Ireland plant announced on Thursday. The Puurs site has played a key role in the production of COVID-19 vaccine shots Pfizer developed with its German partner BioNTech using the messenger RNA (mRNA) technology.

  • Motley Fool

    Why Roivant Sciences' Shares Are Up Thursday

    The company is collaborating with Pfizer to create a portfolio company to develop an encouraging drug to treat ulcerative colitis.

  • Financial Times

    US warns Beijing it cannot control Covid-19 without western jabs

    Beijing will be unable to control the spread of Covid-19 unless it imports foreign-made vaccines that are more effective than Chinese-made jabs, Joe Biden’s coronavirus tsar has warned. Ashish Jha, who runs the US coronavirus response, said in an interview at a conference organised by the FT and the Commonwealth Fund that all the empirical evidence suggests Chinese-made Covid vaccines are “not as good” as mRNA shots made by Moderna, BioNTech and Pfizer. Other Covid vaccines based on different technologies developed in the UK and elsewhere, such as the University of Oxford-AstraZeneca jab, are also superior to vaccines made in China, he added.